KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) focus on developing protein therapeutics

Boston, MA 06/07/2013 (wallstreetpr) – KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) in the previous trading session closed at $5.15 after going down by $0.29 (-5.33%) which closed at $5.44 in the previous trading session of Wednesday. The stock opened its day at $5.36 and hit the day’s low at $4.90 and the day’s high at $5.42. The volume in the previous trading session was close to 0.052 million which was higher than the average volume of 0.033 million shares measured over 1 month period. The relative volume of the stock is 0.97 which is the ratio of current volume and the average volume of the three months. The short float on the total floated shares is about 1.20% while the short ratio is about 4.88. Analysts are targeting the price at $13.00. The current ratio is 8.20 which mean the company has more assets than liabilities. The average true range of the stock is 0.24.

KaloBios Pharmaceuticals is a company which is based in United States and is engaged in developing protein therapeutics. The company engineers and develops protein therapeutics and antibodies. Its technology of monoclonal antibodies is used for the reengineering of the antibodies with items which re developed in the fields of oncology, autoimmunity and infectious disease. RSI (Relative Strength Index) is a technical analysis indicator using which we can measure the fear in a given stock. So, there has been news recently about KaloBios Pharmaceuticals that it has gone in an oversold region. Hence the bullish investor, by looking at RSI, thinks that this high selling is going to exhaust and move in a buy line.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact ir@edm.media.

Published by Pushpa Naresh

Pushpa Naresh has done MBA (Finance) and an avid market tracker. She is a technical analyst who closely tracks US markets along with other global markets like India. She has been expressing her views about markets and also advises various clients.

Recent Stories

SignUp Now For Our Featured Newsletter